News | February 27, 2026
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Under the deal, Quiver will receive an undisclosed advance payment and research support
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
Subscribe To Our Newsletter & Stay Updated
